查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1804269

呼吸道融合病毒（RSV）(RSV)治療的全球市場:各藥物類型，各劑型，各地區 - 市場規模，產業動態，機會分析，預測(2025年～2033年)

Global Respiratory Syncytial Virus Treatment Market: Drug Type, Dosage Form, Region-Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 237 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球呼吸道合胞病毒 (RSV) 治療市場正呈現快速顯著的成長，這反映出全球日益認識到 RSV 是一項重大公共衛生課題。 2024 年，該市場規模約為 23.872 億美元，預計未來十年將大幅成長，到 2033 年將達到 83.325 億美元。這一驚人成長意味著預測期內的複合年增長率為 14.9%。推動這一擴張的因素有很多，包括呼吸道合胞病毒疫苗的普及、診斷基礎設施的加強以及公眾和臨床對呼吸道合胞病毒疾病認識的不斷提高。

目前，北美在全球呼吸道合胞病毒治療市場中處於領先地位，得益於疫苗的早期審批、充足的研發資金以及能夠支持廣泛疾病控制和預防工作的完善的醫療保健基礎設施。尤其是在美國，呼吸道合胞病毒仍然是一個嚴重的健康問題，尤其對於嬰兒和老年人等弱勢群體（如嬰幼兒和老年人而言。根據美國疾病管制與預防中心 (CDC) 2024 年發布的估計，呼吸道合胞病毒每年將導致 360 萬至 650 萬人次門診就診、19 萬至 35 萬人次住院治療以及高達 2.3 萬人次死亡。這些驚人的數字凸顯了有效預防和治療策略的必要性。

值得關注的市場發展

在呼吸道合胞病毒 (RSV) 疫苗市場，知名製藥和生技公司正在積極尋求創新，這反映出有效的呼吸道合胞病毒 (RSV) 預防策略日益重要。 Moderna、賽諾菲、葛蘭素史克、阿斯特捷利康、輝瑞、Enanta Pharmaceuticals、Bavarian Nordic、Novavax 和 BlueWillow Biologics 等領先公司處於新型疫苗開發和臨床研究的前沿，致力於滿足各年齡層人群在預防呼吸道合胞病毒方面尚未滿足的需求。

近期進展的一個顯著例子是輝瑞的 ABRYSVO，於 2025 年 4 月 1 日獲得歐盟 (EU) 批准，用於治療 18 至 59 歲成年人的下呼吸道疾病。此核准是基於III期MONet研究（NCT05842967）的數據，該研究顯示ABRYSVO具有良好的安全性、耐受性良好，並能誘導強大的免疫反應。這項監管里程碑使ABRYSVO成為歐盟範圍內最廣泛有效的RSV疫苗，不僅涵蓋18歲及以上的成年人，還涵蓋透過母親接種的6個月以下嬰兒。

除了輝瑞的進展外，三葉草生物製藥在RSV疫苗領域也取得了重大進展。 2025年3月23日，三葉草生物獲得美國食品藥物管理局（FDA）的授權，啟動其候選疫苗SCB-1019的I期臨床試驗。這項臨床試驗旨在評估SCB-1019對已接種葛蘭素史克AREXVY（一種已獲批准的呼吸道合胞病毒疫苗）的老年患者的加強效果。

關鍵生長因子

呼吸道合胞病毒 (RSV) 仍然是全球面臨的重大健康課題，尤其影響嬰幼兒。該病毒是這群脆弱人群下呼吸道感染的主要原因之一，常常導致需要醫療幹預的嚴重疾病。光是在美國，RSV 每年估計導致5歲以下兒童門診210萬人次，凸顯了這種感染的廣泛性。

RSV 相關的住院治療也是這項負擔的重要方面，光是在美國，每年就有5.8萬至8萬名5歲以下兒童住院。這些住院治療通常伴隨嚴重呼吸窘迫、支氣管炎和肺炎等併發症，需要密切監測和支持性治療。高住院率不僅反映了幼兒呼吸道合胞病毒 (RSV) 感染的嚴重程度，還會導致醫療成本和資源利用率的上升。

本報告分析了全球呼吸道合胞病毒 (RSV) 治療市場，提供了每個細分市場的市場規模和預測、市場動態和趨勢以及公司概況。

目錄

第1章 調查架構

  • 目的
  • 產品概要
    • 市場區隔
    • 市場與市場區隔定義

第2章 調查手法

第3章 全球呼吸道融合病毒（RSV）(RSV)治療市場概要

  • 產業價值鏈分析
    • 研究·製劑
    • 開發·包裝
    • 銷售·流通
    • 終端用戶
  • 產業預測
    • 流行病學和患者族群
    • 各國的呼吸道融合病毒（RSV）(RSV)治療的流行病學
    • 呼吸道融合病毒（RSV）(RSV)的治療和管理
    • 未滿足需求
    • 已上市的藥物
    • 新藥
    • 對象族群和呼吸道融合病毒（RSV）(RSV)疫苗
    • 正在開發的呼吸道融合病毒（RSV）(RSV)疫苗
  • 大環境分析
  • 波特的五力分析
  • 市場動態和趨勢
    • 主要趨勢
    • 成長促進因素
    • 阻礙因素/課題
  • 市場成長及預測
    • 市場收益的估計與預測(2020年～2033年)
    • 價格分析
  • COVID-19對市場成長趨勢的影響的評估
    • 成長趨勢的轉移的分析
    • 產業的最佳業務實踐
  • 法規形勢

第4章 競爭儀表板

  • 市場集中率
  • 企業的市場佔有率分析(金額)(2024年)
  • 競爭製圖

第5章 呼吸道融合病毒（RSV）(RSV)治療市場分析:各藥物類型

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • Ribavirin
    • Synagis
    • Virazole
    • Palivizumab
    • Riba Tab
    • 其他

第6章 呼吸道融合病毒（RSV）(RSV)治療市場分析:各劑型

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • 口服劑
    • 注射劑
    • 吸入劑
    • 其他

第7章 呼吸道融合病毒（RSV）(RSV)治療市場分析:各治療類型

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • 免疫預防
    • 支持療法
    • 抗病毒藥物

第8章 呼吸道融合病毒（RSV）(RSV)治療市場分析:各流通管道

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • 醫院藥局
    • 藥妝店
    • 零售藥局
    • 診療所

第9章 呼吸道融合病毒（RSV）(RSV)治療市場分析:各區各國

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第10章 北美的呼吸道融合病毒（RSV）(RSV)治療市場分析

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • 各藥物類型
    • 各劑型
    • 各治療類型
    • 各流通管道
    • 各國

第11章 歐洲的呼吸道融合病毒（RSV）(RSV)治療市場分析

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • 各藥物類型
    • 各劑型
    • 各治療類型
    • 各流通管道
    • 各國

第12章 亞太地區的呼吸道融合病毒（RSV）(RSV)治療市場分析

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • 各藥物類型
    • 各劑型
    • 各治療類型
    • 各流通管道
    • 各國

第13章 中東·非洲的呼吸道融合病毒（RSV）(RSV)治療市場分析

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • 各藥物類型
    • 各劑型
    • 各治療類型
    • 各流通管道
    • 各國

第14章 南美的呼吸道融合病毒（RSV）(RSV)治療市場分析

  • 重要的知識見解
  • 市場規模與預測(2020年～2033年)
    • 各藥物類型
    • 各劑型
    • 各治療類型
    • 各流通管道
    • 各國

第15章 企業簡介

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Atea Pharmaceuticals
  • Bausch Health Companies Inc.
  • Celltrion Inc.
  • Enanta Pharmaceuticals, Inc
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson's
  • mAbxience
  • Medivir AB
  • Merck Co., Inc.
  • Pfizer Inc.
  • ReViral Ltd.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • 其他的企業
簡介目錄
Product Code: AA0821085

The global respiratory syncytial virus (RSV) treatment market is experiencing rapid and substantial growth, reflecting the increasing recognition of RSV as a major public health challenge worldwide. Valued at approximately USD 2,387.2 million in 2024, the market is projected to expand significantly over the coming decade, reaching an estimated USD 8,332.5 million by 2033. This impressive growth corresponds to a compound annual growth rate (CAGR) of 14.9% during the forecast period. Several factors are driving this expansion, including the rising adoption of RSV vaccines, enhancements in diagnostic infrastructure, and growing public and clinical awareness of the disease.

North America currently leads the global RSV treatment market, benefiting from a combination of early vaccine approvals, substantial funding for research and development, and a well-established healthcare infrastructure capable of supporting widespread disease management and prevention efforts. In the United States specifically, RSV continues to pose a significant health concern, particularly for vulnerable populations such as infants and the elderly. According to estimates from the Centers for Disease Control and Prevention (CDC) in 2024, RSV was responsible for between 3.6 and 6.5 million outpatient visits, 190,000 to 350,000 hospitalizations, and up to 23,000 deaths annually. These staggering figures underscore the critical need for effective prevention and treatment strategies.

Noteworthy Market Developments

Several prominent pharmaceutical and biotechnology companies are actively driving innovation in the respiratory syncytial virus (RSV) vaccine market, reflecting the growing importance of effective RSV prevention strategies. Leading players such as Moderna, Sanofi, GSK, AstraZeneca, Pfizer, Enanta Pharmaceuticals, Bavarian Nordic, Novavax, and BlueWillow Biologics are at the forefront of developing new vaccines and advancing clinical research to address the unmet needs in RSV protection across different age groups.

A notable example of recent progress is Pfizer's ABRYSVO, which received approval from the European Union on April 1, 2025, for use in adults aged 18 to 59 years with lower respiratory tract disease. This approval was supported by data from the Phase 3 MONet trial (NCT05842967), which demonstrated that ABRYSVO has a strong safety profile, is well tolerated, and elicits a robust immune response. With this regulatory milestone, ABRYSVO has become the vaccine offering the broadest RSV protection in the EU, covering adults 18 years and older as well as infants up to six months of age through maternal immunization.

In addition to Pfizer's advances, Clover Biopharmaceuticals has also made significant strides in the RSV vaccine field. On March 23, 2025, Clover received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial for its candidate vaccine SCB-1019. This trial is designed specifically to evaluate the booster efficacy of SCB-1019 in older adults who have previously been vaccinated with GSK's AREXVY, an RSV vaccine already approved for this population.

Core Growth Drivers

Respiratory syncytial virus (RSV) remains a major global health challenge, with a particularly profound impact on infants and young children. This virus is one of the leading causes of lower respiratory tract infections in this vulnerable population, often resulting in severe illness that necessitates medical intervention. In the United States alone, RSV is responsible for an estimated 2.1 million outpatient visits annually among children under the age of five, highlighting the widespread nature of the infection.

Hospitalizations due to RSV also represent a critical aspect of this burden, with between 58,000 and 80,000 children under five admitted to hospitals each year in the U.S. alone. These hospital stays are often required for cases involving severe respiratory distress or complications, such as bronchiolitis or pneumonia, which demand close monitoring and supportive care. The high number of hospital admissions not only reflects the severity of RSV infections in young children but also contributes to increased healthcare costs and resource utilization.

Emerging Opportunity Trends

The rollout of respiratory syncytial virus (RSV) vaccines represents a major advancement in the prevention of respiratory diseases, marking a significant milestone in public health efforts to protect vulnerable populations, especially infants and the elderly. These vaccines have proven effective in reducing the incidence and severity of RSV infections, which historically have posed a serious threat due to limited preventive options. Their introduction has not only improved clinical outcomes but also paved the way for innovative approaches to respiratory disease management.

Building on the success of recent RSV vaccine launches, pharmaceutical companies such as AstraZeneca and Moderna are actively developing next-generation vaccines that combine RSV protection with immunization against other significant respiratory illnesses. These combination vaccines aim to streamline immunization schedules, enhance patient compliance, and provide comprehensive protection by targeting multiple viruses simultaneously.

Barriers to Optimization

Respiratory syncytial virus (RSV) disease represents a significant health burden, particularly in low- and middle-income countries (LMICs), where it is a leading cause of severe respiratory illness and mortality among infants and young children. In these regions, the impact of RSV is particularly devastating due to limited access to healthcare resources, insufficient infrastructure, and the vulnerability of young populations.

The virus contributes to high rates of hospitalization and long-term respiratory complications, placing immense strain on families and healthcare systems already stretched thin by other public health challenges. Addressing RSV in LMICs is therefore a critical priority for reducing childhood morbidity and mortality. For example, recently approved drugs such as Beyfortus and Abrysvo, which offer promising protection against RSV, are priced at levels that are prohibitive for many families and healthcare providers operating within constrained budgets. Beyfortus, priced at approximately USD 414.75 per dose, and Abrysvo, costing around USD 230.00 per dose

Detailed Market Segmentation

By Dosage Form, injectables currently dominate the dosage form segment, holding an overwhelming market share exceeding 85%. This dominance reflects a strong preference within the medical community and patients for injectable therapies, which are widely recognized for their rapid onset of action and high clinical efficacy. The growing acceptance and utilization of vaccines and monoclonal antibodies (mAbs) have been significant drivers behind this trend.

By Drug Type, vaccines hold a dominant position in the drug market, commanding over 50% of the total market share. This leadership is largely driven by the recent approvals of new vaccines and their expanding application across a broader range of age groups, from infants and children to adults and the elderly. The growing awareness of preventive healthcare, coupled with increased public health initiatives and vaccination campaigns, has significantly boosted demand for vaccines worldwide. As a result, this segment has experienced robust growth, becoming a major contributor to the overall market.

Segment Breakdown

By Drug Type

  • Vaccines
    • Abrysvo
    • Arexvy
    • MRESVIA
  • Monoclonal Antibodies
    • Synagis
    • Beyfortus
  • Antivirals

By Dosage Forms

  • Injectables
  • Orals
  • Antivirals

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Western Europe
      • The UK
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Western Europe
    • Eastern Europe
      • Poland
      • Russia
      • Rest of Eastern Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of MEA
  • South America
    • Argentina
    • Brazil
    • Rest of South America

Leading Market Participants

  • Moderna
  • Sanofi
  • GSK
  • AstraZeneca
  • Pfizer
  • Enanta Pharmaceuticals, Inc
  • Bavarian Nordic
  • Novavax
  • BlueWillow Biologics
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Objective
  • 1.2. Product Overview
    • 1.2.1. Market Segmentation
    • 1.2.2. Market & Segment Definitions
  • 1.3. Research Methodology
    • 1.3.1. List of Primary & Secondary Sources
    • 1.3.2. Market Size Estimation
      • 1.3.2.1. Assumption for the Study
      • 1.3.2.2. Data Triangulation

Chapter 3. Global Respiratory Syncytial Virus Treatment Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Research and Formulation
    • 3.1.2. Development and Packaging
    • 3.1.3. Sales and Distribution
    • 3.1.4. End Users
  • 3.2. Industry Outlook
    • 3.2.1. Epidemiology and Patient Population
      • 3.2.1.1. Key Findings
      • 3.2.1.2. Epidem and Market Methodology
      • 3.2.1.3. 8MM Incident Patient Population of Respiratory Syncytial Virus Treatment
    • 3.2.2. Country Wise-Epidemiology of Respiratory Syncytial Virus Treatment
      • 3.2.2.1. United States Epidemiology
        • 3.2.2.1.1. Assumptions and Rationale
        • 3.2.2.1.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the United States
        • 3.2.2.1.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the United States
        • 3.2.2.1.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in United States
        • 3.2.2.1.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the United States
      • 3.2.2.2. EU5 Epidemiology
        • 3.2.2.2.1. Germany
          • 3.2.2.2.1.1. Assumptions and Rationale
          • 3.2.2.2.1.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the Germany
          • 3.2.2.2.1.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the Germany
          • 3.2.2.2.1.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in Germany
          • 3.2.2.2.1.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the Germany
        • 3.2.2.2.2. France
          • 3.2.2.2.2.1. Assumptions and Rationale
          • 3.2.2.2.2.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the France
          • 3.2.2.2.2.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the France
          • 3.2.2.2.2.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in France
          • 3.2.2.2.2.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the France
        • 3.2.2.2.3. Italy
          • 3.2.2.2.3.1. Assumptions and Rationale
          • 3.2.2.2.3.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the Italy
          • 3.2.2.2.3.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the Italy
          • 3.2.2.2.3.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in Italy
          • 3.2.2.2.3.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the Italy
        • 3.2.2.2.4. Spain
          • 3.2.2.2.4.1. Assumptions and Rationale
          • 3.2.2.2.4.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the Spain
          • 3.2.2.2.4.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the Spain
          • 3.2.2.2.4.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in Spain
          • 3.2.2.2.4.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the Spain
        • 3.2.2.2.5. United Kingdom
          • 3.2.2.2.5.1. Assumptions and Rationale
          • 3.2.2.2.5.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the UK
          • 3.2.2.2.5.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the UK
          • 3.2.2.2.5.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in UK
          • 3.2.2.2.5.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the UK
      • 3.2.2.3. Japan Epidemiology
        • 3.2.2.3.1. Assumptions and Rationale
        • 3.2.2.3.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the Japan
        • 3.2.2.3.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the Japan
        • 3.2.2.3.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in Japan
        • 3.2.2.3.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the Japan
      • 3.2.2.4. China Epidemiology
        • 3.2.2.4.1. Assumptions and Rationale
        • 3.2.2.4.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the China
        • 3.2.2.4.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the China
        • 3.2.2.4.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in China
        • 3.2.2.4.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the China
      • 3.2.2.5. India Epidemiology
        • 3.2.2.5.1. Assumptions and Rationale
        • 3.2.2.5.2. Total Incident Cases of Respiratory Syncytial Virus Treatment in the India
        • 3.2.2.5.3. Case-Specific Incidence of Respiratory Syncytial Virus Treatment in the India
        • 3.2.2.5.4. Age-Specific Incidence of Respiratory Syncytial Virus Treatment in India
        • 3.2.2.5.5. Incidence of Respiratory Syncytial Virus Treatment by Extremities (%) in the India
    • 3.2.3. Treatment and Management of Respiratory Syncytial Virus Treatment
      • 3.2.3.1. Scope of Treatment
      • 3.2.3.2. Treatment Guidelines
      • 3.2.3.3. American Academy of Pediatrics guidelines for Respiratory Syncytial Virus Treatment
    • 3.2.4. Unmet Needs
    • 3.2.5. Marketed Drugs
      • 3.2.5.1. Synagis (Palivizumab): MedImmune/Abbott Laboratories Inc.
        • 3.2.5.1.1. Product Description
        • 3.2.5.1.2. Regulatory Milestones
        • 3.2.5.1.3. Clinical Development
        • 3.2.5.1.4. Ongoing Current Pipeline Activity
        • 3.2.5.1.5. Safety and efficacy
        • 3.2.5.1.6. Product Profile
      • 3.2.5.2. Virazole (Ribavirin): ICN Pharmaceuticals
        • 3.2.5.2.1. Product Description
        • 3.2.5.2.2. Regulatory Milestones
        • 3.2.5.2.3. Clinical Development
        • 3.2.5.2.4. Ongoing Current Pipeline Activity
        • 3.2.5.2.5. Safety and efficacy
        • 3.2.5.2.6. Product Profile
    • 3.2.6. Emerging Drugs
      • 3.2.6.1. EDP 938: Enanta Pharmaceuticals
        • 3.2.6.1.1. Product Description
        • 3.2.6.1.2. Other Development Activities
        • 3.2.6.1.3. Clinical Development
        • 3.2.6.1.4. Clinical Trials Information
        • 3.2.6.1.5. Safety and Efficacy
        • 3.2.6.1.6. Product Profile
      • 3.2.6.2. Nirsevimab: AstraZeneca
        • 3.2.6.2.1. Product Description
        • 3.2.6.2.2. Other Development Activities
        • 3.2.6.2.3. Clinical Development
        • 3.2.6.2.4. Clinical Trials Information
        • 3.2.6.2.5. Safety and Efficacy
        • 3.2.6.2.6. Product Profile
      • 3.2.6.3. MEDI8897: MedImmune LLC
        • 3.2.6.3.1. Product Description
        • 3.2.6.3.2. Other Development Activities
        • 3.2.6.3.3. Clinical Development
        • 3.2.6.3.4. Clinical Trials Information
        • 3.2.6.3.5. Safety and Efficacy
        • 3.2.6.3.6. Product Profile
      • 3.2.6.4. JNJ-53718678: Janssen Sciences Ireland UC
        • 3.2.6.4.1. Product Description
        • 3.2.6.4.2. Other Development Activities
        • 3.2.6.4.3. Clinical Development
        • 3.2.6.4.4. Clinical Trials Information
        • 3.2.6.4.5. Safety and Efficacy
        • 3.2.6.4.6. Product Profile
    • 3.2.7. Target population and RSV vaccine
      • 3.2.7.1. Maternal
      • 3.2.7.2. Infants
      • 3.2.7.3. Children
      • 3.2.7.4. Elderly
    • 3.2.8. RSV Vaccines in pipeline
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Dynamics and Trends
    • 3.5.1. Key Trends
    • 3.5.2. Growth Drivers
    • 3.5.3. Restraints/ Challenges
  • 3.6. Market Growth and Outlook
    • 3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
    • 3.6.2. Pricing Analysis
  • 3.7. Covid-19 Impact Assessment on Market Growth Trend
    • 3.7.1. Growth Trend Shift Analysis
    • 3.7.2. Industry Best Practices
  • 3.8. Regulatory Landscape

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2024
  • 4.3. Competitor Mappin

Chapter 5. Respiratory Syncytial Virus Treatment Market Analysis, By Drug type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 5.2.1. Ribavirin
    • 5.2.2. Synagis
    • 5.2.3. Virazole
    • 5.2.4. Palivizumab
    • 5.2.5. Riba Tab
    • 5.2.6. Others

Chapter 6. Respiratory Syncytial Virus Treatment Market Analysis, By Dosage Form

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 6.2.1. Oral
    • 6.2.2. Injectable
    • 6.2.3. Inhaler
    • 6.2.4. Others

Chapter 7. Respiratory Syncytial Virus Treatment Market Analysis, By Treatment Type

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 7.2.1. Immune prophylaxis
    • 7.2.2. Supportive care
    • 7.2.3. Antiviral Medications

Chapter 8. Respiratory Syncytial Virus Treatment Market Analysis, By Distribution Channel

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 8.2.1. Hospital pharmacies
    • 8.2.2. Drug Stores
    • 8.2.3. Retail pharmacies
    • 8.2.4. Clinics

Chapter 9. Respiratory Syncytial Virus Treatment Market Analysis, By Region/Country

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 9.2.1. North America
      • 9.2.1.1. The U.S.
      • 9.2.1.2. Canada
      • 9.2.1.3. Mexico
    • 9.2.2. Europe
      • 9.2.2.1. The UK
      • 9.2.2.2. Germany
      • 9.2.2.3. France
      • 9.2.2.4. Italy
      • 9.2.2.5. Spain
      • 9.2.2.6. Poland
      • 9.2.2.7. Russia
      • 9.2.2.8. Rest of Europe
    • 9.2.3. Asia Pacific
      • 9.2.3.1. China
      • 9.2.3.2. India
      • 9.2.3.3. Japan
      • 9.2.3.4. Australia & New Zealand
      • 9.2.3.5. ASEAN
      • 9.2.3.6. Rest of Asia Pacific
    • 9.2.4. Middle East & Africa
      • 9.2.4.1. UAE
      • 9.2.4.2. Saudi Arabia
      • 9.2.4.3. South Africa
      • 9.2.4.4. Rest of MEA
    • 9.2.5. South America
      • 9.2.5.1. Argentina
      • 9.2.5.2. Brazil
      • 9.2.5.3. Rest of South America

Chapter 10. North America Respiratory Syncytial Virus Treatment Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 10.2.1. By Drug type
    • 10.2.2. By Dosage form
    • 10.2.3. By Treatment type
    • 10.2.4. By Distribution channel
    • 10.2.5. By Country

Chapter 11. Europe Respiratory Syncytial Virus Treatment Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)11.2.1. By Drug type
    • 11.2.2. By Dosage form
    • 11.2.3. By Treatment type
    • 11.2.4. By Distribution channel
    • 11.2.5. By Country

Chapter 12. Asia Pacific Respiratory Syncytial Virus Treatment Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 12.2.1. By Drug type
    • 12.2.2. By Dosage form
    • 12.2.3. By Treatment type
    • 12.2.4. By Distribution channel
    • 12.2.5. By Country

Chapter 13. Middle East & Africa Respiratory Syncytial Virus Treatment Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 13.2.1. By Drug type
    • 13.2.2. By Dosage form
    • 13.2.3. By Treatment type
    • 13.2.4. By Distribution channel
    • 13.2.5. By Country

Chapter 14. South America Respiratory Syncytial Virus Treatment Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 14.2.1. By Drug type
    • 14.2.2. By Dosage form
    • 14.2.3. By Treatment type
    • 14.2.4. By Distribution channel
    • 14.2.5. By Country

Chapter 15. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 15.1. AbbVie, Inc.
  • 15.2. AstraZeneca PLC
  • 15.3. Atea Pharmaceuticals
  • 15.4. Bausch Health Companies Inc.
  • 15.5. Celltrion Inc.
  • 15.6. Enanta Pharmaceuticals, Inc
  • 15.7. F. Hoffmann-La Roche AG
  • 15.8. Gilead Sciences, Inc.
  • 15.9. GlaxoSmithKline PLC
  • 15.10. Johnson & Johnson's
  • 15.11. mAbxience
  • 15.12. Medivir AB
  • 15.13. Merck Co., Inc.
  • 15.14. Pfizer Inc.
  • 15.15. ReViral Ltd.
  • 15.16. Sanofi
  • 15.17. Teva Pharmaceutical Industries Ltd.
  • 15.18. Other players